Evaluating the risk-to-benefit ratio of using cotrimoxazole as a Pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: a retrospective study with 494 patients.

It seems that due to the low incidence of PCP in pemphigus patients treated with rituximab, prophylactic cotrimoxazole therapy is not necessary and it only increases the overall therapy cost and might cause cotrimoxazole-related adverse effects in some patients. However, regarding its probable beneficial effect in patients with long-term history of immunosuppressive therapy, more studies are required. This article is protected by copyright. All rights reserved.